Physician profile
Herbert Allen
NPI 1033188487
$6,865.76
in general payments reported to CMS, 2019-2025
30 companies · $2,096 in 2025
The $2,096 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.93 · 2020: $17.94 · 2021: $267 · 2022: $1,022 · 2023: $1,768 · 2024: $1,651 · 2025: $2,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,514.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,981.13 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.29 | 2022-2024 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $450.80 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $432.25 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $366.41 | 2022-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $349.35 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $333.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $304.86 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $280.88 | 2022-2023 | Rebyota, Cimzia |
| Lilly USA, LLC | $229.60 | 2024-2025 | Omvoh |
| Pfizer INC. | $204.13 | 2021-2025 | |
| Genzyme Corporation | $186.36 | 2023-2025 | |
| Janssen Biotech, INC. | $166.43 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $163.80 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $148.06 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $100.00 | 2024 | Zymfentra |
| Gilead Sciences, INC. | $90.35 | 2023-2025 | |
| Braintree Laboratories, INC. | $84.88 | 2021-2024 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.70 | 2024-2025 | Ofev |
| Vivus LLC | $57.56 | 2025 | Pancreaze |
| Merck Sharp & Dohme LLC | $53.31 | 2023-2024 | Dificid |
| Neuraxis, INC. | $48.90 | 2025 | |
| Aurinia Pharma U.S., INC. | $47.47 | 2023-2025 | Lupkynis |
| Evoke Pharma, INC. | $44.91 | 2023-2024 | Gimoti |
| Ucb, INC. | $41.49 | 2024-2025 | Bimzelx, Cimzia |
| Actelion Pharmaceuticals US, INC. | $37.91 | 2023-2024 | Opsumit, Uptravi |
| Aimmune Therapeutics, INC. | $24.28 | 2025 | Zenpep |
| Ethicon US, LLC | $22.79 | 2022 | |
| Amgen INC. | $19.22 | 2023 | Avsola, Amjevita |
| Genentech USA, INC. | $18.81 | 2023 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.